Products - Blood and bone marrow cancers | Topic | NICE

Showing 38 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 January 2026
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 February 2026
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
19 January 2026
Expected publication date:
11 February 2026
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 February 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 March 2026
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 March 2026
Suspected Cancer: recognition and referral (update)
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
2 February 2026
Expected publication date:
25 March 2026
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 April 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
22 April 2026
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
7 May 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
30 January 2026
Expected publication date:
13 May 2026
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 July 2026
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 June 2027
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 July 2027
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC